MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Pipeline Review, H1 2016
SKU ID :GMD-10222459 | Published Date: 30-Jun-2016 | No. of pages: 40Description
TOC
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) Overview 6
Therapeutics Development 7
MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Products under Development by Stage of Development 7
MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Products under Development by Therapy Area 8
MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Products under Development by Indication 9
MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Products under Development by Companies 12
MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Products under Development by Universities/Institutes 14
MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 20
eFFECTOR Therapeutics, Inc. 20
Eli Lilly and Company 21
Merck & Co., Inc. 22
Selvita S.A. 23
MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Drug Profiles 24
cercosporamide - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
eFT-508 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ETC-027 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
ETC-17804452 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
ETC-219 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
SEL-201 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
SLV-2436 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Inhibit MAPKAP Kinase 2 for Inflammation - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules to Inhibit MNK1 and MNK2 for Oncology - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Inhibit Mnk2 for Acute Myeloid Leukemia - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Dormant Projects 36
MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) - Featured News & Press Releases 37
Mar 18, 2016: eFFECTOR Therapeutics to Present at the American Association for Cancer Research 2016 Annual Meeting 37
Jun 19, 2015: Peer-Reviewed Study in Cell Validates eFFECTOR Therapeutics' Novel Small-Molecule Approach to Cancer Treatment 37
Jan 06, 2015: eFFECTOR Therapeutics Initiates Dosing in Phase 1/2 Clinical Trial of eFT508 in Solid Tumors 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40
Tables & Figures
List of Tables
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Route of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 19
Pipeline by eFFECTOR Therapeutics, Inc., H1 2016 20
Pipeline by Eli Lilly and Company, H1 2016 21
Pipeline by Merck & Co., Inc., H1 2016 22
Pipeline by Selvita S.A., H1 2016 23
Dormant Projects, H1 2016 36
List of Figures
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Actions, H1 2016 17
Number of Products by Stage and Routes of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 19
Companies
eFFECTOR Therapeutics, Inc.
Eli Lilly and Company
Merck & Co., Inc.
Selvita S.A.
- PRICE
-
$3500$10500